Event context and recent share performance

Tandem Diabetes Care (TNDM) has been drawing attention after a recent stretch of mixed share performance, with gains over the past month and past year, set against weaker results over the past 3 years and 5 years.

The current US$21.59 share price comes after a 13.93% 1 month share price return and a 12.62% 1 year total shareholder return. However, the 3 year and 5 year total shareholder returns remain deeply negative, suggesting that shorter term momentum contrasts with a weaker long term record.

If Tandem’s recent move has you looking at other diabetes and medical technology names, this can be a good moment to scan 33 healthcare AI stocks for potential next ideas to research.

With annual revenue of US$1.01b, a reported net loss of US$204.71m, a value score of 4, and a current US$21.59 share price sitting below some valuation estimates, is this a potential entry point or is future growth already priced in?

Most Popular Narrative: 25.3% Undervalued

At a last close of $21.59 versus a narrative fair value of $28.91, the widely followed Tandem Diabetes Care storyline leans toward upside potential based on discounted cash flow assumptions and analyst forecasts.

Advancements in product pipeline, including the upcoming launches of Steadiset extended wear infusion sets and Tubeless Mobi, reinforce innovation leadership and enable participation in the sustained shift toward automated, user-friendly pump solutions. This is expected to support both topline growth and gross margin expansion.

Want to see what sits behind that product optimism and cash flow outlook? The narrative leans on specific revenue, margin and earnings targets that could surprise you.

Result: Fair Value of $28.91 (UNDERVALUED)

However, you still need to watch execution risks around the PayGo and pharmacy rollout, as well as intensifying pump competition, which could challenge the optimistic margin and cash flow story.

Next Steps

Mixed messages on value and execution risk can be hard to weigh on your own, so take a moment to review the numbers directly and form your own stance. You can start with 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this story has sparked your curiosity, do not stop here. The real edge often comes from comparing a few carefully chosen ideas side by side.

• Prioritize quality by reviewing companies filtered for stronger fundamentals through our solid balance sheet and fundamentals stocks screener (42 results). This could help you steer toward sturdier financial profiles.
• Hunt for value opportunities using our screener containing 26 high quality undiscovered gems, where underfollowed names with solid metrics might still be flying under the radar.
• Dial down risk by scanning 68 resilient stocks with low risk scores, which focuses on businesses that score better on our internal risk checks so you are not caught off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.